CHINA-HI-TECH-FAIR
10.11.2020 16:10:05 CET | Business Wire | Press release
Themed "Transforming Future with Technology, Driving Development with Innovation", the 22nd China High-Tech Fair (CHTF2020) will open on November 11-15, 2020.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201110005830/en/
As the trend-setter of the hi-tech industry, CHTF will provide a glimpse of the future technologies with its “3 Highlights” and “5 Trends”.
Highlight 1: "13th Five-Year" technological achievements
State-level exhibitors including the Ministry of Commerce, the Ministry of Science and Technology, the State Intellectual Property Office, the Chinese Academy of Sciences, and the Ministry of Industry and Information Technology will display technology-related achievements of China’s 13th Five-Year Plan.
Highlight 2: Online show to facilitate overseas exhibitors
Despite the COVID-19 pandemic, 41 countries and international organizations have confirmed to participate in the offline fair, including Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Czech Republic, and Germany. For those who cannot come in person, the “Belt and Road” and International Pavilions will provide online exhibition opportunities.
Highlight 3: Multiple activities to integrate industries, universities and research institutions
CHTF2020 will gather domestic and foreign leading enterprises, technology SMEs, MAKERS, financing institutions, as well as global government officials, entrepreneurs, economists and scholars to discuss policies and make academic exchanges.
Trend 1: AI entering daily life
CHTF2020 will witness more companies embracing "AI + industry". Huawei will bring full-stack, full-scenario solutions and provide development platforms for the governments and enterprises. With a new set of algorithm ecology, channel ecology, and manufacturing ecology, major high-tech companies are making AI technology available to everyone.
Trend 2: Emerging anti-epidemic technologies
CHTF2020 will display new anti-epidemic technologies and products, and their latest applications.
Trend 3: Commercial deployment of 5G
Commercial 5G applications, including 5G smart poles, 5G micro-stations, 5G smart home, and 5G telemedicine will be showcased on the Information Technology and Products Exhibition at Hall 1.
Trend 4: Cutting-edge technologies
About 50 institutes will exhibit at the Pavilion of the Chinese Academy of Sciences.
Trend 5: Smart city
The CHTF Smart City Exhibition will showcase Smart City Ecological Construction, AI Application, 5G, Cloud Computing and Big Data, IoT, Mobile Application and Smart Hardware. Asia-Pacific Smart City Development Summit will also be held.
For more: http://www.chtf.com/english/
View source version on businesswire.com: https://www.businesswire.com/news/home/20201110005830/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse
Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release
Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom